Mayo Clinic
The purpose of this study is to evaluate the safety and immunogenicity of autologous DC vaccine in recurrent respiratory papillomatosis patients
Inclusion Criteria: * Clinically confirmed diagnosis of recurrent respiratory papillomatosis. * Patients with papillomas in the laryngeal mucosa at the time of recruitment and patients with records of recurrent papillomas in laryngeal mucosa at least once in the past 6-12 months at the time of recruitment. NOTE: The presence of papillomas in laryngeal mucosa or clinical records of the presence of papillomas in laryngeal mucosa is required. * Human papilloma virus (HPV)6+ RRP in larynx * ECOG (Eastern cooperative oncology group performance test) performance status 0 or 1 (Appendix I). * The fo…
Each patient will receive 5 doses autologous immunotherapy intradermally.
Arctuva estimate
Verify or correct the compensation shown for this listing.